Absci (NASDAQ:ABSI) Announces Quarterly Earnings Results

Key Points

• Absci reported quarterly EPS of -$0.19, matching consensus, while revenue of $0.30 million came in below analysts’ $0.66 million estimate.
• The company expects interim 13-week data from its ABS-201 pattern hair-loss trial in December 2026 and full 26-week data in early 2027. Blinded data so far indicate the drug is well tolerated, but do not establish efficacy.
• Absci ended the quarter with $173.7 million in cash and equivalents, which management expects to fund operations into the second half of 2028; its planned Phase 2 endometriosis trial is now expected to start in mid-2027.

Absci (NASDAQ:ABSI - Get Free Report) issued its earnings results on Thursday. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19), FiscalAI reports. Absci had a negative net margin of 7,756.38% and a negative return on equity of 61.71%. The company had revenue of $0.30 million during the quarter, compared to analysts' expectations of $0.66 million.

Here are the key takeaways from Absci's conference call:

• Absci expects to report interim 13-week pattern hair loss data in December 2026 and full 26-week proof-of-concept data in early 2027. Management characterized the interim readout as directional and said it will not change the ongoing trial.
• The company said blinded aggregate data to date show ABS-201 is well tolerated, and its estimated half-life may support two or three injections over six months. These findings are preliminary and do not yet establish efficacy.
• Absci now anticipates starting its planned phase II endometriosis trial in mid-2027, with doses to be selected after reviewing HEADLINE trial data. The company estimates the program could reach more than $4 billion in peak sales if development succeeds.
• Cash, cash equivalents and marketable securities totaled $173.7 million at quarter-end, down from $201.1 million at June 30; management expects funding to last into the second half of 2028. Quarterly R&D expenses rose to $23.6 million from $19.2 million a year earlier, while SG&A increased to $9 million from $8.4 million.
• Management cited consumer research suggesting that 30–35 additional target-area hairs per square centimeter at 26 weeks could support strong adoption, and estimated a $25 billion U.S. pattern hair loss market. These are company estimates based on hypothetical product profiles, not clinical results.

Absci Stock Performance

Shares of Absci stock traded down $0.38 during midday trading on Thursday, hitting $9.74. 3,005,329 shares of the company traded hands, compared to its average volume of 4,307,210. The firm's fifty day moving average price is $9.65 and its 200-day moving average price is $6.75. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -12.24 and a beta of 2.22. Absci has a 12 month low of $2.24 and a 12 month high of $12.54.

Key Stories Impacting Absci

Investors following ABSI have been watching these stories:

• Positive Sentiment: Absci said its Phase 2 HEADLINE trial of ABS-201 for pattern hair loss remains on track, with 13-week proof-of-concept data expected in December 2026 and 26-week results expected in early 2027. The data could be an important clinical catalyst. Absci reports business updates and third-quarter results
• Positive Sentiment: The company reported $173.7 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2028. It also plans to start a Phase 2 ABS-201 trial for endometriosis in mid-2027. Absci reports third-quarter loss as ABS-201 trial advances
• Neutral Sentiment: Absci appointed Gerry Muhle, a former Galderma executive with experience launching prescription biologics, as chief commercial officer. The hire adds commercial expertise, though its impact depends on future pipeline progress. Absci appoints Gerry Muhle as chief commercial officer

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Jefferies Financial Group started coverage on shares of Absci in a research note on Thursday, October 29th. They issued a "buy" rating and a $14.00 price objective on the stock. Guggenheim restated a "buy" rating on shares of Absci in a research note on Monday, September 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of Absci in a report on Wednesday, September 23rd. Lifesci Capital began coverage on Absci in a research note on Wednesday, September 9th. They issued an "outperform" rating on the stock. Finally, HC Wainwright reissued a "buy" rating on shares of Absci in a report on Tuesday, October 20th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Absci has a consensus rating of "Moderate Buy" and an average price target of $14.50.

Absci Company Profile

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.